Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/059440external-prioritypatent/WO2010010127A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2011000012A1publicationCriticalpatent/TN2011000012A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim 1, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis.
TN2011000012A2009-07-222011-01-13Sphingosine 1 phosphate receptor modulateors and their use to treat muscle inflammation
TN2011000012A1
(en)
PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units.